Olanzapine: Preclinical and clinical profiles of a novel antipsychotic agent

CNS Drug Reviews

Volumn 6, Issue 4, 2000, Pages 303-363

  Tollefson, Gary D ^a   Taylor, Cindy C ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic agent; Dopamine antagonist; Olanzapine; Schizophrenia; Serotonin antagonist

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CLOZAPINE; DOPAMINE RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROLACTIN; RISPERIDONE; SEROTONIN RECEPTOR;

CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; INSOMNIA; LONG TERM CARE; META ANALYSIS; NONHUMAN; PROLACTIN BLOOD LEVEL; QT INTERVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECEPTOR AFFINITY; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SOMNOLENCE; SUICIDE ATTEMPT; TARDIVE DYSKINESIA;

EID: 0034440855     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.2000.tb00155.x     Document Type: Review

References (278)

1. Ai D, Roper TA, Riley JA. Diabetic ketoacidosis and clozapine. Postgrad Med 1998;74:493-494.
2. Al-Mulhim A, Atwal S, Coupland NJ. Provocation of obsessive-compulsive behaviour and tremor by olanzapine [letter]. Can J Psychiatry 1998;43:645.
3. Alphs LD, Lee HS. Comparison of withdrawal of typical and atypical antipsychotic drugs: A case study. J Clin Psychiatry 1991;52:346-348.
4. Altamura AC, Velona I, Curreli R, Bravi D. Olanzapine in the treatment of paranoid schizophrenia (Abstract). Eur Neuropsychopharmacol 1999;9(Suppl 5):S297.
5. 3H]SCH23390 binding in vivo. Eur J Pharmacol 1986;120:143-144.
6. Andreasen NC. Negative symptoms in schizophrenia. Arch Gen Psychiatry 1982;39:784-788.
7. Apple JE, Van Hauer G. Neuroleptic malignant syndrome associated with olanzapine therapy [letter]. Psychosomatics 1999;40:267-268.
8. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: Inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol 1982;51:321-329.
9. Bailey LG, Maxwell S, Brandabur MM. Substance abuse as a risk factor for tardive dyskinesia: A retrospective analysis of 1,027 patients. Psychopharmacol Bull 1997;33:177-181.
10. Baker RW, Ames D, Umbricht DG, Chengappa KN, Schooler NR. Obsessive-compulsive symptoms in schizophrenia: A comparison of olanzapine and placebo. Psychopharmacol Bull 1996;32:89-93.
11. Baldacchino AM, Stubbs JH, Nevison-Andrews D. The use of olanzapine in noncompliant or treatment-resistant clozapine populations in hospital. Pharm J 1998;260:207-209.
12. Baldwin DS, Montgomery SA. First clinical experience with olanzapine (LY170053): Results of an open-label safety and dose-ranging study in patients with schizophrenia. Int Clin Psychopharmacol 1995:10:239-244.
13. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676.
14. Bartholini G. Interactions of striatal dopaminergic, cholinergic and GABA-ergic neurons: Relation to extrapyramidal function. Trends Pharmacol Sci 1980;138-140.
15. Basson BR, Kinon BJ, Taylor CC, Tollefson GD. Factors influencing weight change in patients with schizophrenia treated with olanzapine versus haloperidol or risperidone (Abstract). 51st Institute on Psychiatric Services, New Orleans, LA 1999.
16. Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV. Olanzapine versus haloperidol: Acute-phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997;7:125-137.
17. Beasley CM, Sanger T, Satterlee W, et al. Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 1996;124:159-167.
18. Beasley CM, Tollefson G, Tran P. Safety of olanzapine. J Clin Psychiatry 1997;58(Suppl 10):13-17.
19. Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996;14:111-123.
20. Beasley CM Jr., Dellva MA, Tamura RN, et al. A randomised, double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry 1999;174:23-30.
21. Beasley CM, Jr., Hamilton SH, Dossenbach M. Relapse prevention with olanzapine. Eur Neuropsychopharmacol 2000;10(Suppl 3):S304
22. Benazzi F. Olanzapine-induced psychotic mania in bipolar schizo-affective disorder [letter]. Eur Psychiatry 1999;14:410-411.
23. Benazzi F, Rossi E. Mania induced by olanzapine. Human Psychopharmacol 1998;13:585-586.
24. Bergstrom RF, Callaghan JT, Kassahun K, Hunt TL, et al. Pharmacokinetics of olanzapine in elderly and young (Abstract). Pharm Res 1995;12:S-358.
25. Bergstrom RF, Mitchell M, Jewell H, Richards J, Hatcher B. Examination of safety, tolerance, and pharmacokinetics of intramuscular (IM) olanzapine compared to oral olanzapine in healthy subjects (Abstract). Schizophr Res 1999;36:305-306.
26. Beuzen J-N, Taylor N, Wesnes K, Wood A. The effect of olanzapine on cognition and psychomotor function in healthy elderly volunteers. J Psychopharmacol 1999;13:152-158.
27. Birchwood M, Mason R, Macmillan F, Healy J. Depression, demoralization and control over psychotic illness: A comparison of depressed and nondepressed patients with a chronic psychosis. Psychol Med 1993:23:387-395.
28. Bissette G, Nemeroff CB. The neurobiology of neurotensin. In: Bloom F, Kupfer D, eds. Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press. 1995:573-583.
29. Bleuler E. Dementia praecox or the group of schizophrenias. New York, NY: International Universities Press; 1950.
30. Bolden C, Cusack B, Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J Pharm Exp Ther 1992;260:576-580.
31. Borison RL, Diamond BI, Sinha E, etal. Clozapine withdrawal rebound psychosis. Psychopharmacol Bull 1988;24:260-263.
32. Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 1994;151:20-26.
33. Breier A, Buchanan RW, Waltrip II RW, Listwak S, Holmes C, Goldstein DS. The effect of clozapine on plasma norepinephrine: Relationship to clinical efficacy. Neuropsychopharmacology 1994;10:1-7.
34. Breier A, Hamilton SH. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 1999;45:403-411.
35. Breier A, Wolkowitz OM, Doran AR, et al. Neuroleptic responsivity of negative and positive symptoms in schizophrenia. Am J Psychiatry 1987;144:1549-1555.
36. Buckley PF. Substance abuse in schizophrenia: A review. J Clin Psychiatry 1998;59(Suppl 3):26-30.
37. Burkhard PR, Vingerhoets FJ, Alberque C, Landis T. Olanzapine-induced neuroleptic malignant syndrome [letter]. Arch Gen Psychiatry 1999;56:101-102.
38. Bymaster F, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:87-96.
39. 1-adrenergic and muscarinic receptors in vivo in rats. Psychopharniacology 1996:124:87-94.
40. 1-adrenergic receptors in vitro. Schizophr Res 1999;37:107-122.
41. Bymaster FP, Rasmussen K, Calligaro DO, et al. In vitro and in vivo biochemistry of olanzapine: A novel, atypical antipsychotic drug. J Clin Psychiatry 1997;58(Suppl 10):28-36.
42. Caldwell CB, Gottesman II. Schizophrenia - A high-risk factor for suicide: Clues to risk reduction. Suicide Life-Threat Behav 1992;22:479-493.
43. Callaghan JT, Cerimele BJ, Kassahun KJ, Nyhart EH, Hoyes-Beehler PJ, Kondraske GV. Olanzapine: Interaction study with imipramine. J Clin Pharmacol 1997;37:971-978.
44. Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995;10(Suppl3):105-114.
45. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996;57(Suppl 11):40-45.
46. Chang KD, Ketter TA. Mood stabilizer augmentation with olanzapine in acutely manic children. J Child Adolesc Psychopharmacol 2000;10:45-49.
47. Charatan FBE, Bartlett NG. The effect of chlorpromazine ("Largactil") on glucose tolerance. J Mental Sci 1955;101:351-353.
48. Chue P, Jones B, Adams C. Use of the olanzapine rapidly-disintegrating tablet in schizophrenia (Abstract). Schizophr Res 1999;36:283.
49. Clark WS, Street JS, Cannon KS, Sanger TM, Tollefson GD, Breier A. Olanzapine in the prevention of psychosis among nursing home patients with behavioral disturbances associated with Alzheimer's dementia (Abstract). Eur Neuropsychopharmacol 1999;9(Suppl 5):S297
50. Clark WS, Street JS, Sanger TM, Breier A. Reduction of psychotic symptoms in patients with Lewy bodylike symptoms treated with olanzapine (Abstract). Neurology 2000;54(Suppl 3):A75.
51. Colli A, Cocciolo M, Francobandiera F, Rogantin F, Cattalini N. Diabetic ketoacidosis associated with clozapine treatment [letter]. Diabetes Care 1999;22:176-177.
52. Conley RR, Kelly DL, Gale EA. Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 1998;33:95-101.
53. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998;155:914-920.
54. Cools AR, Prinssen EPM, Ellenbroek BA. The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: Effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine. Psychopharmacology 1995;119:428-439.
55. Corbett R, Camacho F, Woods AT, et al. Antipsychotic agents antagonize noncompetitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology 1995;120:67-74.
56. Costa e Silava JA, Alvarez N, Mazotti G, et al. Olanzapine as alternative therapy for patients intolerant to haloperidol-induced EPS: Results of a multicenter, collaborative trial in Latin America. J Clin Psychopharmacol 2000;In press.
57. 3 receptor antagonist GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 1987;92:881-894.
58. Crawford AMK, Beasley CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997;26:41-54.
59. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-483.
60. Czekalla J, Beasley CM, Berg PH, Dellva MA, Grundy S. Cardiac safety profile of olanzapine based on preclinical and clinical ECG data (Abstract). Eur Newopsychopharmacol 1999;9(Suppl 5):S293.
61. Das S, Fowler SC. Similarity of clozapine's and olanzapine's acute effects on rats' lapping behavior. Psychopharmacology 1996;123:374-378.
62. David SR, Taylor CC, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin concentrations in patients with schizophrenia. Clin Terapeutics 2000;22:1085-1096.
63. Davies LM, Drummond MF. The economic burden of schizophrenia. Psychiatr Bull 1990;14:522-525.
64. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 1991;148:1474-1486.
65. Dellva MA, Tran P, Tollefson GD, Wentley AL, Beasley CM Jr. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997:48:1571-1577.
66. Deutch AY, Lee MC, Iadarola MJ. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action. Mol Cell Neurosci 1991;3:332-341.
67. Dirksen-Kauerz U, Pietz K, Kanitz RD, Wetterling T, Arolt V, Dittmann R. Experiences with olanzapine: Are epileptic seizures side effects due to this atypical neuroleptic? (Abstract). Pharmacopsychiatry 1997;30:161.
68. Dixon L. Dual diagnosis of substance abuse in schizophrenia: Prevalence and impact on outcomes. Schizophr Res 1999;35(Suppl):S93-S100.
69. .Dossenbach MRK, Beuzen J-N, Avnon M, et al. The effeictiveness of olanzapine in the treatment of refractory schizophrenia patients that are unresponsive or unable to tolerant clozapine. Clin Ther 2000;22:1021-1034.
70. 2 dopamine receptor antagonists induce Fos and related proteins in rat striatal neurons. Neuroscience 1990;37:287-294.
71. Edgell ET, Gregor KJ, Cockburn I. Letter to the editor, re: Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin Therapeutics 1999;21:917-924.
72. Package insert. Olanzapine. Indianapolis, IN: Eli Lilly and Co., 1996.
73. Ellenbroek BA. Treatment of schizophrenia: A clinical and preclinical evaluation of neuroleptic drugs. Pharmacol Ther 1993;57:1-78.
74. Emborg C. Neuroleptic malignant syndrome after treatment with olanzapine. Ugeskrift for Laeger 1999;161:1424-1425.
75. Ereshefsky L. Pharmacokinetics and drug interactions: Update for new antipsychotics. J Clin Psychiatry 1996;57(Suppl 11):12-25.
76. 2-dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine - relation to extrapyramidal side effects. Arch Gen Psychiatry 1992;49:538-544.
77. Fertig MK, Brooks VG, Shelton PS, English CW. Hyperglycemia associated with olanzapine. J Clin Pyschiatry 1998;59:687-689.
78. Filice GA, McDougall BC, Ercan-Fang N, Billington CJ. Neuroleptic malignant syndrome associated with olanzapine. Ann Pharmacotherapy 1998;32:1158-1159.
79. Fitton A, Heel RC. Clozapine, a review of its pharmacological properties and therapeutic use in schizophrenia. Drugs 1990;40:722-747.
80. Fitzgerald MJ, Pinkofsky HB, Brannon G, Dandridge E, Calhoun A. Olanzapine-induced mania [letter]. Am J Psychiatry 1999; 156:1114.
81. Foster RU, Goa KL. Olanzapine: A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1999; 15:611-640.
82. Frazier JA, Biederman J, Jacobs TG, et al. Olanzapine in the treatment of bipolar disorder in juveniles (Abstract). Eur Neuropsychopharmacol 2000;10(Suppl 3):S247.
83. Friedman JH, Goldstein S, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: Results of an open label pilot study. clin Neuropharmacol 1998;21:285-288.
84. Fuller RW, Snoddy HD. Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine, an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 1992;77:87-93.
85. Gao X-M, Sakai K, Tamminga CA. Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared with haloperidol. Neuropsychopharmacology 1998;19:428-433.
86. Garcia LM, Cipres L, de Cendra E, Vilalta FJ. Neuroleptic malignant syndrome associated with olanzapine [letter]. Med Clin 1999;113:239.
87. Gatta B, Rigalleau V, Gin H. Diabetic ketoacidosis with olanzapine treatment. Diabetes Care 1999;22:1002-1003.
88. Gerlach J, Peacock L. New antipsychotics: The present status, Int Clin Psychopharmacol 1995;10:39-48.
89. Gheorghiu S, Knobler HY, Drumer D. Recurrence of neuroleptic malignant syndrome with olanzapine treatment [letter]. Am J Psychiatry 1999;156:1836.
90. Gilmore JA, Kinon BJ, Basson BR, Tollefson GD. Effect of long-term olanzapine treatment on weight change in schizophrenia (Abstract). Eur Neuropsychopharmacol 2000; 10(Supl 3):S305.
91. Goldman-Rakic P. Cerebral cortical mechanisms in schizophrenia. Neuropsvchopharmacology 1994;10:22S-27S.
92. Goldstein LE, Sporn J, Brown S, et al. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 1999;40:438-443.
93. Gomez J-C, Sacristan JA, Hernandez J, et al. The safety of olanzapine compared with other antipsychotic drugs: Results of an observational prospective study in patients with schizophrenia (EFESO study). J Clin Psychiatry 2000;61:335-343.
94. Goncalves N, Gruneberg F. Oral glucose tolerance test, on one single occasion, in scizophrenics under long-term neuroleptic treatment (translated from German). Pharmakopsychiatry 1997;8:289-295.
95. Graham JM, Sussman JD, Ford KS, Sagar HJ. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: A cautionary note. J Neural Neurosurg Psychiatry 1998;65:774-777.
96. Green AI, Brown WA. Prolactin and neuroleptic drugs. Endocrinol Metab Clin North Am 1988;17:213-223.
97. Griffith RW, Saameli K. Clozapine and agranulocytosis. Lancet 1975;2:657.
98. Guy W. ECDEU Assessment Manual for Psychopharmacology. Bethesda, MD: US Department of Health, Education and Welfare, 1976.
99. Haggarty JM, Husni M, Peat C, Allain S. Atypical neuroleptic malignant syndrome? [letter]. Can J Psychiatry 1999;44:711-712.
100. Hamilton SH, Genduso LA, Revicki DA. Medical resource use and work and socioeconomics in the treatment of schizophrenia: Olanzapine compared with haloperidol (Abstract). Eur Neuropsychopharmacol 1997;7:S203.
101. Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr. Olanzapine versus placebo and haloperidol: Quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1997;18:41-49.
102. Hanel RA, Sandmann MC, Kranich M, De Bittencourt PR. Neuroleptic malignant syndrome: Case report with recurrence associated with the use of olanzapine. Arquivos de Neuro-Psiquiatria 1998;56:833-837.
103. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr Bull 1997;23:567-582.
104. Hauptmann B, Kupsch A, Arnold G. Hyperglycemia associated with low-dose clozapine treatment. J Neural Transm 1999;106: XII.
105. Hayek DV, Huttl V, Reiss J, Schweiger HD, Fuessl HS. Hyperglycemia and ketoacidosis under olanzapine (translated from German). Nervenarzt 1999;70:836-837.
106. Häfner H, an der Heiden W. Epidemiology of schizophrenia. Can J Psychiatry 1997;42:139-151.
107. Hickey C, Stewart C, Lippmann S. Olanzapine and NMS [letter]. Psychiatr Serv 1999;50:836-837.
108. Ho B-C, Miller D, Nopoulos P, Andreasen NC. A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia. J Clin Psychiatry 1999;60:658-663.
109. Horrigan JP, Barnhill LJ, Courvoisie HE. Olanzapine in PDD. J Am Acad Child Adolesc Psychiatry 1997;36:1166-1167.
110. Huttunen M. The evolution of the serotonin-dopamine antagonist concept. J Clin Psychopharmacol 1995;15(Suppl 1):4S-10S.
111. Hyde TM, Weinberger DR. Seizures and schizophrenia.Schizophr Bull 1997;23:611-622.
112. Ichikawa J, Kuroki T, Dai J, Meltzer HY. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. Eur J Pharmacol 1998;351:163-171.
113. Jakovljevic M, Dossenbach M, Friedel P, et al. Olanzapine versus fluphenazine in the acute (6-week) treatment of schizophrenia. Psychiatr Danubina 1999;11:3-10.
114. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-1308.
115. Jimenez-Jimenez FJ, Tallon-Barranco A, Orti-Pareja M, Zurdo M, Porta J, Molina JA. Olanzapine can worsen parkinsonism. Neurology 1998;50:1183-1184.
116. John V, Rapp M, Pies R. Aggression, agitation, and mania with Olanzapine [letter]. Can J Psychiatry 1998;43:1054.
117. Johnson V, Bruxner G. Neuroleptic malignant syndrome associated with olanzapine. Austr New Zealand J Psych 1998;32:884-886.
118. Kane JM. Treatment-resistant schizophrenic patients. J Clin Psychiatry 1996;57(Suppl 9):35-40.
119. Kane JM, Honigfeld G, Singer J, Meltzer H, for The Clozaril Collaborative Study Group. Clozapíne for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
120. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatiy 1999;156:286-293.
121. 2 receptor occupancy of olanzapine in schizophrenia: A PET investigation. Am J Psychiatry 1998;155:921-928.
122. Kassahun K, Mattiuz EL, Nyhart EH Jr., et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Disp 1996;25:81-93.
123. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
124. Kemner C. An open-label study of olanzapine in children with pervasive developmental disorder (Abstract). Eur Neuropsychopharmacol 1999;9(Suppl 5):S287-S288.
125. Kennedy JS, Basson BR, Clark WS, et al. The effects of olanzapine on Alzheimer's disease assessment scale scores in patients with mild to moderate Alzheimer's disease with psychosis and behavioral disturbances (Abstract). Banff Psychiatric Conference, Banff, Alberta 1999.
126. Keskiner A, Toumi AE, Bousquet T. Psychotropic drugs, diabetes and chronic mental patients. Psychosomatics 1973;16:176-181.
127. Ketter TA, Winsberg ME, DeGolia SG, Dunai M, Tate DL, Strong CM. Rapid efficacy of olanzapine augmentation in nonpsychotic bipolar mixed states. J Clin Psychiatry 1998;59:83-85.
128. Kinon BJ, Basson BR, Malcolm SK, Stauffer VL. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. J Clin Psychiatry 2000;61:833-840.
129. Kinon BJ, Basson BR, Wang J, Malcolm SK, Stauffer VL. Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone (Abstract). Eur Newopsychopharmacol 2000;10(Suppl 3):S306.
130. Kinon BJ, Targum SD, Milton D, Johnston SE. Olanzapine in the management of behavioral disturbances and/or psychosis in demented nursing home patients (Abstract). 39th New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, Boca Raton, Florida, 1999.
131. Klieser E, Schulte T, Wurthmann C, et al. Open-label study of olanzapine in generalized anxiety disorder (GAD) (Abstract). 12th European College of Neuropsychopharmacology (ECNP), London, UK 1999.
132. Korenyi C, Lowenstein B. Chlorpromazine-induced diabetes. Dis Nerv System 1968;827-828.
133. Kostakoglu AE, Yazici KM, Erbas T, Guvener N. Ketoacidosis as a side-effect of clozapine: A case report. Acta Psychiatr Scand 1996;93:217-218.
134. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry 1994;151:1520-1521.
135. Kuroki T, Meltzer HY, Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharm Exp Ther 1999;288:774-781.
136. Leal D, Galanter M, Dermatis H, Westreich L. Correlates of protracted homelessness in a sample of dually diagnosed psychiatric inpatients. J Subst Abuse Treatment 1999;16:143-147.
137. Lecrubier Y, Bouhassira M, Olivier V, Lancrenon S, Crawford AM. Olanzapine versus amisulpride and placebo in the treatment of negative symptoms and deficit states of chronic schizophrenia (Abstract). Eur Neuropsychopharmacol 1999;9(Suppl 5):S288.
138. Lee J, Crismon M, Dorson P. Seizure associated with olanzapine. Ann Pharmacother 1999;33:554-556.
139. Leiberman JA, Safferman AZ. Clinical profile of clozapine: Adverse reactions and agranulocytosis. Psychiatr Quart 1992;63:51-70.
140. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizphr Res 1999;35:51-68.
141. Levenson JL. Neuroleptic malignant syndrome after the initiation of olanzapine [letter]. J Clin Psychopharmacol l999;19:477-478.
142. 2 receptors. Psychopharmacology 1993;112:S40-S54.
143. Li X-M, Perry KW, Wong DT, Bymaster FP. Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacology 1998;136:153-161.
144. Lindenmayer JP. Olanzapine-induced ketoacidosis with diabetes mellitus [letter]. Am J Psychiatry 1999;156:1471.
145. Lindenmayer JP, Klebanov R. Olanzapine-induced manic-like syndrome [letter]. J Clin Psychiatry 1998;59:318-319.
146. London JA. Mania associated with olanzapine. J Am Acad Child Adolesc Psychiatry 1998;37:135-136.
147. Loza N, EI-Dosoky AM, Okasha TA, et al. Olanzapine compared with chlorpromazine in acute schizophrenia (Abstract). Eur Neuropsychopharmacol 1999;9(Suppl 5):S291.
148. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: Observations on possible mechanism. Eur J Clin Pharmacol 1998;54:639-643.
149. Malek-Ahmadi P, Simonds JF. Olanzapine for autistic disorder with hyperactivity [letter]. J Am Acad Child Adolesc Psychiatry 1998;37:902.
150. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder [letter]. Am J Psychiatry 2000;156:1834-1835.
151. Marcus EL, Vass A, Zislin J. Marked elevation of serum creatine kinase associated with olanzapine therapy. Ann Pharmacother 1999;33:697-700.
152. Margolese HC, Chouinard G. Olanzapine-induced neurolėptic malignant syndrome with mental retardation [letter]. Am J Psychiatry 1999;156:1115-1116.
153. Martin J, Gomez J-C, Garcia-Bernardo E, et al. Olanzapine in treatment-refractory schizophrenia: Results of an open-label study. J Clin Psychiatry 1997;58:479-483.
154. Mattiuz E, Franklin R, Gillespie T, et al. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metab Dispos 1997;25:573-583.
155. Maule S, Giannella R, Lanzio M, Villari V. Diabetic ketoacidosis with clozapine treatment. Diab Nutrit Metab 1999;12:187-188.
156. McElroy SL, Frye MA, Denikoff KD, et al. Olanzapine in treatment-resistant bipolar disorder. J Affect Disor 1998;49:119-122.
157. McKee HA, D'Arcy PF, Wilson PJK. Diabetes and schizophrenia: A preliminary study. J Clin Hosp Pharmacy 1986;11:297-299.
158. Meltzer HY. The mechanism of action of novel antipsychotic drugs. Schizophr Bull 1991;17:263-287.
159. Meltzer HY. Suicide in schizophrenia: Rísk factors and clozapine treatment. J Clin Psychiatry 1998;59(Suppl 3):15-20.
160. i values. J Pharn Exp Ther 1989;251:238-246.
161. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull 1989;25:390-392.
162. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Res 1999;25:233-255.
163. 1) affects food intake in rats. J Nutr 1994;124:1029-1036.
164. Merchant KM, Dobner PR, Dorsa DM. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J Neurosci 1992;12:652-663.
165. Merchant KM, Dorsa DM. Differential induction of neurotehsin and c-fos gene expression by typical versus atypical antipsychotics. Proc Natl Acad Sci USA 1993;90:3447-3451.
166. Modestin J. Ammann R. Mental disorder and criminality: male schizophrenia. Schiophr Bull 1996;22:69-82.
167. Molho ES. Factor SA. Worsening of motor features of parkinsonism with olanzapine. Mov Disord 1999;14:1014-1016.
168. Moltz DA, Coeytaux RR. Case report: Possible neuroleptic malignant syndrome associated with olanzapine [letter]. J Clin Psychopharmacol 1998; 18:485-486.
169. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
170. Moore NA, Calligaro DO, Wong TD, Bymaster F, Tye NC. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drugs 1993;2:281-293.
171. Moore NA, Rees G, Sanger G. Differential effects of olanzapine and other antipsychotic agents on stimulant-induced hyperactivity (Abstract). Psychopharmacology 1994;8(Suppl 1):S29.
172. Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel "atypical". antipsychotic agent. J Pharm Exp Ther 1992;262:545-551.
173. 2A receptor blockade. J Pharm Exp Ther 1999;288:590-596.
174. Morrison D, Clark D, Goldfarb E, McCoy L. Worsening of obsessive-compulsive symptoms following treatment with olanzapine [letter]. Am J Psychiatry 1998;155:855.
175. Mottard J-P, De La Sablonnière J-F. Olanzapine-induced obsessive-compulsive disorder [letter]. Am J Psychiatry 1999;156:799-800.
176. Möller U-J. Neuroleptic treatment of negative symptoms in schizophrenic patients: Efficacy problems and methodological difficulties. Eur Neuropsychopharmacol 1993;3:1-11.
177. Möller H-J. The negative component in schizophrenia. Acta Psychiatr Scand 1995;91(Suppl 388):11-14.
178. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Comp Psychiatry 1996;37:68-73.
179. Murphy AT, Lake BG, Berstein JR, Franklin RB, Gillespie TA. Characterization of olanzapine (LY170053) in human liver slices by liquid chromatography/tandem mass spectrometry. J Mass Spectrometry 1999;33:1237-1245.
180. Nguyen TV, Kosofsky BE, Birnbaum R, Cohen BM, Hyman SE. Differential expression of c-fos and Zif 268 in rat striatum after haloperidol, clozapine, and amphetamine. Proc Natl Acad Scl USA 1992;89:4270-4274.
181. 1 and D2 receptors in dopamine depleted animals. Psychopharmacology 1999;142:175-181.
182. Ninan I, Kulkarni SK. Preferential inhibition of dizocilpine-induced hyperlocomotion by olanzapine. Eur J Pharmacol 1999;368:1-7.
183. Noordsy DL, O'Keefe C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a community mental health center setting. J Clin Psychiatry 1999;60(Suppl 19):47-53.
184. 2 receptor occupancy in relation to clozapine serum concentration - a PET study in schizophrenic patients. Am J Psychiatry 1995;152:1444-1449.
185. North CS, Pollio DE, Smith EM, Spitznagel EL. Correlates of early onset and chronicity of homelessness in a large urban homeless population. J Nerv Ment Dis 1998;186:393-400.
186. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 1997;16:1-7.
187. Ober SK, Hudak R, Rusterholtz A. Hyperglycemia and olanzapine. Am J Psychiatry 1999;156:970.
188. Obermeyer BD, Nyhart EH Jr., Mattiuz EL, et al. The disposition of olanzapine (OL) in healthy volunteers (Abstract). Pharmacologist 1993;35:176.
189. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962; 10:799-812.
190. Palia SS, Clarke EJ. Clozaril withdrawal syndrome. Psychiatr Bull 1993;17:374-375.
191. Patel BR, Nyhart EH, Callaghan JT, et al. Combined population analysis of olanzapine in healthy volunteers (Abstract). Pharm Res 1995;12: S-415.
192. Pierides M. Clozapine monotherapy and ketoacidosis. Br J Psychiatry 1997;171:90-91.
193. 123I]IBZM single photon emission tomography (SPET) study. Psychopharmacology 1996;124:148-153.
194. Popli AP, Konicki PE, Jurjus GJ, Fuller MA, Jaskiw GE. Clozapine associated diabetes mellitus. J Clin Psychiatry 1997;58:108-111.
195. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with PDD: An open-label pilot study. J Clin Psychopharmacol 1999;19:37-44.
196. Potenza MN, Wasylink S, Longhurst JG, Epperson CN, McDougle CJ. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychopharmacol 1998;18:423-424.
197. Pozo P, Alcantara AG. Mania-like syndrome in a patient with chronic schizophrenia during Olanzapine treatment [letter]. J Psychiatry Neurosci 1998;23:309-310.
198. Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone and Olanzapine. Clin Therapeutics 1998;20:1203-1217.
199. Purdon SE, Jones B, Chouinard G, Stip E, Tollefson GD. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, ripseridone, or haloperidol. Arch Gen Psychiatry 2000;57:249-258.
200. Radke JM, Owens MJ, Ritchie JC, Nemeroff CB. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions. Proc Natl Acad Sci USA 1998;95:11462-11464.
201. Rao ML, Muller HJ. Biochemical findings of negative symptoms in schizophrenia and their putative relevance to pharmacologie treatment. Neuropsychobiology 1994;30:160-172.
202. 3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons. Eur J Pharmacol 1991;205:113-116.
203. Ratakonda S, Miller CE, Gorman JM, Sharif ZA. Efficacy of a 12 week trial of olanzapine in treatment refractory schizophrenia or schizoaffective disorder (Abstract). Schizophr Res 1998;29:150.
204. Ravindran AV, Jones BW, Al-Zaid K, Lapierre YD. Effective treatment of mania with olanzapine: 2 case reports. J Psychiatry Neurosci 1997;22:345-346.
205. Reeves RR, McBride WA, Brannon GE. Olanzapine-induced mania. J Am Osteopath Assoc 1998;98:549-550.
206. Richelson E. Receptor pharmacology of neuroleptics: Relation to clinical effects. J Clin Psychiatry 1999;60(Suppl 10):5-14.
207. Ring BJ, Binkley SN, Vanderbranden M, Wrighton SA. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9. CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996;41:181-186.
208. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharm Exp Ther 1996;276:658-666.
209. Robertson GS, Fibiger HC. Neuroleptics increase c-fos expression in the forebrain: Contrasting effects of haloperidol and clozapine. Neuroscience 1992;46:315-328.
210. Robertson GS, Fibiger HC. Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology 1996;14:105-110.
211. Robertson GS, Matsumura H, Fibiger HC. Induction patterns of neuroleptic-induced Fos-like immunoreactivity as predictors of atypical antipsychotic activity. J Pharm Exp Ther 1994;271:1058-1066.
212. Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharm Exp Ther 1994;268:1403-1410.
213. Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression. J Clin Psychiatry 1999;60:116-118.
214. Roy A, Thompson R, Kennedy S. Depression in chronic schizophrenia. Br J Psychiatry 1983; 142:465-470.
215. Roychoudhury K. Use of olanzapine in children with developmental disabilities and challenging behaviors (Abstract). J Invest Med 1999;47:165A.
216. Rubin M. Use of atypical antipsychotics in children with mental retardation, autism, and other developmental disabilities. Psychiatr Ann 1997;27:219-221.
217. Rudolf J, Ghaemi M, Schmulling S. Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine. Eur Psychiatry 1999;14:356-357.
218. Sanders RD, Mossman D. An open trial of olanzapine in patients with treatment-refractory psychoses. J Clin Psychopharmacol 1999;19:62-66.
219. Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley CM Jr., Tollefson GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999:156:79-87.
220. Sanger TM, Tohen MF, Jacobs TG, et al. Olanzapine in the treatment of rapid-cycling bipolar disorder (Abstract). Eur Neuropsychopharmacol 1999;9(Suppl 5):S246.
221. 1-dopamine receptors in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayedresponse task. J Neurophysiol 1994;71:515-528.
222. Schooler NM, Kane JM. Research diagnosis for tardive dyskinesia [letter]. Arch Gen Psychiatry 1982;39:486-487.
223. Sebens JB, Koch T, Ter Horst GJ, Korf J. Olanzapine-induced Fos expression in the rat forebrain; cross-tolerance with haloperidol and clozapine. Eur J Pharmacol 1998;353:13-21.
224. Seeman P, Lee T, Chang-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature (Lond) 1976;261:717-718.
225. Sharma RP, Janicak PG, Bissette G, Nemeroff CB. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. Am J Psychiatry 1997; 154:1019-1021.
226. Sharma V, Pistor L. Treatment of bipolar mixed state with olanzapine. J Psychiatry Neurosci 1999;24:40-44.
227. Shelton RC, Tollefson GD, Tohen MF, et al. Safety and efficacy of olanzapine plus fluoxetine in treatment-resistant major depressive disorder (Abstract). Schizophr Res 1999;36:297.
228. Shore D. Clinical implications of clozapine discontinuation: Report of an NIMH workshop. Schizophr Bull 1995;21:333-338.
229. Simon AE, Aubry JM, Malky L, Bertschy G. Hypomania-like syndrome induced by olanzapine. Int Clin Psychopharmacol 1999;14:377-378.
230. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 1970; 212:11-19.
231. Sipahimalani A, Masand PS. Olanzapine in the treatment of delirium. Psychosomatics 1999;39:422-430.
232. Siris SG. Depression and schizophrenia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Cambridge, MA: Blackwell Science Ltd, 1995;128-145.
233. Smith H, Kenney-Herbert J, Knowles L. Clozapine-induced diabetic ketoacidosis [letter]. Austr New Zealand J Psych 1999;33:120-121.
234. Sobel M, Jaggers ED, Franz MA. New-onset diabetes mellitus associated with the initiation of quetiapine treatment. J Clin Psychiatry 1999;60:556-557.
235. Stanton J. Weight gain associated with neuroleptic medication: A review. Schizophr Bull 1995;21:463-472.
236. Stockton ME, Rasmussen K. Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 1996;14:97-104.
237. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer's disease in nursing care facilities: Double-blind, randomized, placebo-controlled trial. Arch Gen Psychiatry 1999;57:968-976.
238. Street JS, Clark WS, Juliar BE, Feldman PD, Kadam DL, Breier A. Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in patients with Alzheimer's dementia (Abstract). Banff Psychiatric Conference, Banff, Alberta 1999.
239. Street JS, Tollefson GD, Tohen M, et al. Olanzapine for psychotic conditions in the elderly (Abstract). Psychiatr Ann 2000;30:191-196.
240. 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology 1999;141:175-181.
241. Thomas A, Grainger D, Andersen S, Tollefson G. Olanzapine versus risperidone in the treatment of schizophrenia and related psychotic disorders (Abstract). Schizophr Res 1998;29:147.
242. Thompson J, Chengappa KNR, Good CB, et al. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment. Int Clin Psychopharmacol 1998;13:95-98.
243. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968;124:138-142.
244. Tohen M, Jacobs TG, Feldman PD, et al. Is olanzapine a mood stabilizer? (Abstract). 10th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland, 2000.
245. Tohen M, Sanger T, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702-709.
246. Tohen MF, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. Arch Gen Psych 2000;57:841-849.
247. Tollefson G, Lesar T. Nonketotic hyperglycemia associated with loxapine and amoxapine: Case report. J Clin Psychiatry 1983; 44:347-348.
248. Tollefson GD, Andersen SW, Tran PV. The course of depressive symptoms in predicting relapse in schizophrenia: A double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 1999;46:365-373.
249. Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychialry 1997;154:1248-1254.
250. Tollefson GD, Beasley CM, Tran P, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 1997;154:457-465.
251. Tollefson GD, Dellva MA, Mattler CA, et al. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. J Clin Psychopharmacol 1999;19:435-443.
252. Tollefson GD, Sanger TM. Negative symptoms: A path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997;154:466-474.
253. Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998;43:803-810.
254. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs and symptoms in schizophrenia: A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1998;55:250-258.
255. Tran P, Dellva MA, Tollefson GD, Beasley CM, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997;58:205-211.
256. Tran P, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychiatry 1997; 17:407-418.
257. Tran P, Tollefson GD, Dossenbach M, Jakovljevic M, Kratky P, Crawford AM. Olanzapine versus fluphenazine: Treatment of acute schizophrenic symptomatology including anxiety (Abstract). 38th New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting, Boca Raton, FL 1998.
258. Tran PV, Dellva MA, Tollefson GD, Wentley AL, Beasley CMJ. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998;172:499-505.
259. Tran PV, Tollefson GD, Sanger TM, Lu Y, Berg PH, Beasley CM Jr. Olanzapine versus haloperidol in the treatment of schizoaffective disorder: Acute and long-term therapy. Br J Psychiatry 1999;174:15-22.
260. Tunis SL, Croghan TW, Heilman DK, Johnstone BM, Obenchain RL. Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol. Med Care 1999;37:678-691.
261. Tunis SL, Johnstone BM, Gibson PJ, Loosbrock DL, Dulisse BK. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment for schizophrenia. J Clin Psychiatry 1999;60(Suppl 19):38-45.
262. Vukicevic Z, Zjacic-Rotkvic V. Chlorpromazine in etiology and treatment prognosis of refractory diabetic ketoacidosis (translated from Czech). Pharmacia 1994;32:325-330.
263. Walker Z, Grace J, Overshot R, et al. Olanzapine in dementia with Lewy bodies: A clinical study, Int J Geriatr Psychiatry 1999;14:459-466.
264. Weiden PJ, Shaw E, Mann JJ. Causes of neuroleptic noncompliance. Psychiatr Ann 1986;16:571-575.
265. Weinberger DR. Schizophrenia and the frontal lobe. Trends Neurosci 1988;8:367-370.
266. Weisler RH, Aheam EP, Davidson JR, Wallace CD. Adjunctive use of olanzapine in mood disorders: Five case reports. Ann clin Psychiatry 1997;9:259-262.
267. Wessely S. The Camberwell study of crime and schizophrenia. Soc Psychiatry Psychiatr Epidemiol 1998;33(Suppl 1):S24-S28.
268. White FJ, Wang RY. Differential effects of classical and atypical drugs on A9 and A10 dopamine neurons. Science 1983;221:1054-1057.
269. Wimmer P, Belmaker R, Schneidman M, Treves I, Sapir M, Dossenbach M. Treatment failure with risperidone: Can olanzapine be an alternative therapy? 9th Biennial Winter Workshop on Schizophrenia, Davos, Switzerland 1998.
270. Winn P. Schizophrenia research moves to the prefrontal cortex. Trends Neural Sci 1994;17:265-268.
271. Wirshing DA, Spellberg BJ, Erhart SM, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychiatry 1998;44:778-783.
272. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergsmans PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-1087.
273. Worms P, Broekkamp CLE, Lloyd K. Behavioural effects of neuroleptics. In: Coyle JT, Enna SJ, eds. Neuroleptics: Neurochemical, Behavioral, and Clinical Perspectives. New York, NY: Raven Press, 1983;93-117.
274. Wright P, Birkett MA, Ferchland I, et al. Olanzapine versus clozapine: A double-blind study of intramuscular olanzapine, haloperidol, and placebo in acutely agitated schizophrenic patients (Abstract). Eur Neuropsychopharmacol 2000;10(Suppl 3):S304.
275. Wright P, Kiesler G, Mitchell M, et al. Preliminary results from a study of the safety, efficacy, and pharmacokinetics of intramuscular (IM) olanzapine in patients with acute nonorganic psychosis (Abstract). Schizophr Res 1999;36:318.
276. Wyderski RJ, Starrett WG, Abou-Saif A. Fatal status epilepticus associated with olanzapine therapy. Ann Pharmacother 1999;33:787-789.
277. Zarate CJ, Narendran R, Tohen M, et al. Clinical predictors of acute response with olanzapine in psychotic mood disorders. J Clin Psychiatry 1998;59:24-28.
278. Zeng XP, Le F, Richelson E. Muscarinic rn, receptor activation by some atypical antipsychotic drugs. Eur J Pharmacol 1997;321:349-354.